Development of highly potent non-covalent inhibitors of SARS-CoV-2 3CLpro
Abstract
The SARS-CoV-2 virus is the causal agent of the ongoing pandemic of coronavirus disease 2019 (COVID-19). There is an urgent need for potent, specific antiviral compounds against SARS-CoV-2. The 3C-like protease (3CLpro) is an essential enzyme for the replication of SARS-CoV-2 and other coronaviruses, and thus is a target for coronavirus drug discovery. Nearly all inhibitors of coronavirus 3CLpro reported so far are covalent inhibitors. Here, we report the development of specific, non-covalent inhibitors of 3CLpro. The most potent one, WU-04, effectively blocks SARS-CoV-2 replications in human cells with EC50 values in the 10-nM range. WU-04 also inhibits the 3CLpro of SARS-CoV and MERS-CoV with high potency, indicating that it is a pan-inhibitor of coronavirus 3CLpro. WU-04 showed anti-SARS-CoV-2 activity similar to that of PF-07321332 (Nirmatrelvir) in K18-hACE2 mice when the same dose was administered orally. Thus, WU-04 is a promising drug candidate for coronavirus treatment.
One-Sentence Summary A oral non-covalent inhibitor of 3C-like protease effectively inhibits SARS-CoV-2 replication.
Competing Interest Statement
N.H., L.Z., W.Z., Q.T., H.Y., J.H., and Q.H. are co-inventors of patents that cover 3CLpro inhibitors in this study. Other authors declare no competing interests.
Subject Area
- Biochemistry (11718)
- Bioengineering (8724)
- Bioinformatics (29132)
- Biophysics (14936)
- Cancer Biology (12051)
- Cell Biology (17360)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14146)
- Epidemiology (2067)
- Evolutionary Biology (18269)
- Genetics (12223)
- Genomics (16768)
- Immunology (11844)
- Microbiology (28016)
- Molecular Biology (11560)
- Neuroscience (60822)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3231)
- Physiology (4940)
- Plant Biology (10401)
- Synthetic Biology (2878)
- Systems Biology (7333)
- Zoology (1642)